Gastro-esophageal Reflux Disease (GERD) Enrolling by Invitation Phase 4 Trials for Dexlansoprazole (DB05351)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Enrolling by Invitation4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02759393Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux EsophagitisTreatment